Researchers from Tokyo Medical and Dental University (TMDU) and Ionis Pharmaceuticals, USA, report a modification wherein replacing the RNA strand of a heteroduplex oligonucleotide with DNA may ...

Treatments that target a fragment of the mutant protein that causes Huntington's disease might be more effective than ...

For sure? No. <br><br>But the mRNA follows the "sense" of the sense strand, which seems like a logical and sufficient naming convention. Even if it's really the antisense strand that's used as the ...

Antisense oligonucleotides (ASO) hold great promise for pharmacotherapy. Now, researchers at Tokyo Medical and Dental University (TMDU) and Ionis Pharmaceuticals, advancing their earlier work on a ...

RNA genetic medicines, 1 in both development and clinical use, are highly selective therapeutics that recognize their cognate target DNA or RNA by base pairing. These medicines include CRISPR-Cas9 ...

In recent years, two antisense oligonucleotide therapies have hit the market, at least nine more are in clinical trials for the treatment of neurologic diseases, and nearly two dozen are in ...

TRANSLATING DNA into proteins may be an even more complex business than anyone thought. In the conventional picture, only one of the twin strands that make up the DNA double helix – the so-called ...

Researchers have devised a molecular structural modification that boosts the efficacy of antisense oligonucleotide-based drugs by replacing the RNA strand of a heteroduplex oligonucleotide with DNA.